Figure 3 from Peripheral Blood IFN Responses to Toll-Like Receptor 1/2 Signaling Associate with Longer Survival in Men with Metastatic Prostate Cancer Treated with Sipuleucel-T

<p>IFN-β induction after TLR1/2 stimulation associates with PBMC ELISpot responses to Fluzone, PHA, and CEFT (cytomegalovirus, EBV, Fluzone, and Tetanus peptide pool). <b>A,</b> ELISpot SFU after each indicated stimulant (<i>n</i> = 77 CEFT, <i>n</i> = 79 Fluzone, <i>n</i> = 82 for others). <b>B,</b> Cell type–specific PBMC densities as a percentage of live single cells (bottom) separated by median IFN-β response after TLR1/2 stimulation (<i>n</i> = 106, PRIME study). <b>A</b> and <b>B,</b><i>P</i> values are from unpaired <i>t</i> test; mean + SEM is shown. <b>C,</b> Correlation (Spearman <i>r</i>) of each indicated PBMC (ELISpot), serum (ELISA), or sip-T product metric (CD54 upreg and TNC) output with fold mock IFN-β values after TLR1/2 stimulation; (*) indicates FDR adjusted <i>Q</i> < 0.05. See Supplementary Figs. S4 and S5 for extended data and representative gating. SFU, spot forming units.</p>

Duke Scholars

Author Smita K Nair Surgery, Surgical Sciences

Author Michael Dee Gunn Medicine, Cardiology

Author Michael Brown Neurosurgery, Neuro-Oncology

Author Andrew John Armstrong Medicine, Medical Oncology